Fate Therapeutics (FATE) EBITDA Margin (2012 - 2026)
Fate Therapeutics (FATE) posted EBITDA Margin of 2540.42% for Q1 2026, little changed on a QoQ basis from 2536.23% in Q4 2025, and down 635.0% year-over-year from 474.84% in Q1 2025.
Fate Therapeutics (FATE) EBITDA Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics' EBITDA Margin history runs 14 years deep, the most recent figure standing at 2540.42% for Q1 2026.
- Quarterly EBITDA Margin fell 635.0% year-over-year to 2540.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2207.47% (down 70400.0% YoY) and the FY2025 annual result came in at 2222.45%, down 67982.0% from the prior year.
- EBITDA Margin was 2540.42% for Q1 2026 at Fate Therapeutics, roughly flat from 2536.23% in the prior quarter.
- Across five years, EBITDA Margin topped out at 48.48% in Q1 2023 and bottomed at 6705.79% in Q2 2023.
- A 5-year average of 1983.62% and a median of 1995.12% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 625774 bps — and 2024, when it soared 604006 bps.
- Fate Therapeutics' EBITDA Margin stood at 145.23% in 2022, then plunged by 1875 bps to 2868.44% in 2023, then decreased by 16 bps to 3319.78% in 2024, then rose by 24 bps to 2536.23% in 2025, then decreased by 0 bps to 2540.42% in 2026.
- Business Quant data shows FATE's EBITDA Margin at 2540.42% in Q1 2026, 2536.23% in Q4 2025, and 1995.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -2,540.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,540.42% |
| Dec 31, 2025 | -2,536.23% |
| Sep 30, 2025 | -1,995.12% |
| Jun 30, 2025 | -1,938.54% |
| Mar 31, 2025 | -2,534.07% |
| Dec 31, 2024 | -3,319.78% |
| Sep 30, 2024 | -1,703.87% |
| Jun 30, 2024 | -665.73% |
| Mar 31, 2024 | -2,652.88% |
| Dec 31, 2023 | -2,868.44% |
| Sep 30, 2023 | -2,637.81% |
| Jun 30, 2023 | -6,705.79% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | -145.23% |
| Sep 30, 2022 | -576.67% |
| Jun 30, 2022 | -448.05% |
| Mar 31, 2022 | -404.40% |
| Dec 31, 2021 | -406.48% |
| Sep 30, 2021 | -383.99% |
| Jun 30, 2021 | -348.78% |